# Ocular Therapeutix Inc. (OCUL) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $10.64, market value $2.3 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Ocular Therapeutix Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 44.9×**. Each dollar of revenue is priced at 44.9×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 4.5×**. The shares trade at 4.5× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -10.9%** (5-yr avg -15.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -603.0%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -511.9%**. The company reported a net loss over the last twelve months.
- **Return on equity: -40.6%**. Return on equity is negative because earnings are negative.
- **Return on assets: -37.3%**. Each dollar of assets produces -37.3% of profit.

## Growth
- **Revenue growth (1 yr): -18.5%** (3-yr 0.3%/yr, 5-yr 24.4%/yr). Revenue fell 18.5% over the last year, against 24.4% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -16.4%**. Earnings per share fell 16.4%, roughly in step with revenue.

## Financial health
- **Current ratio: 15.39** (quick 15.39). Current assets cover the next year's liabilities 15.39 times.
- **Altman Z-score: 10.30**. A Z-score of 10.30 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Ocular Therapeutix Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (11 analysts). 11 analysts cover Ocular Therapeutix Inc.; the consensus is strong_buy, with an average price target of $27.09 (+155% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -16.2%** (YTD -12.4%, 3-mo 29.0%). The shares are down 16.2% over twelve months including dividends.
- **From 52-week high: -35.3%** (70.8% above the low). Trading 35% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 56**. An RSI of 56 is neutral.
- **Beta (1 yr): 0.98** (volatility 71%). Beta of 0.98 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=OCUL · Page: https://foliofundamentals.com/stocks/ocul

Not investment advice.